Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Kivu Bioscience Inc.
BeOne Medicines
Eli Lilly and Company
NiKang Therapeutics, Inc.
MacroGenics
SystImmune Inc.
SN BioScience
Incyte Corporation
NiKang Therapeutics, Inc.
Pfizer
University of Virginia
Incyte Corporation
Theratechnologies
Inspirna, Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
AstraZeneca
Xencor, Inc.
Advaxis, Inc.
Zhejiang University
University of Florida
SCRI Development Innovations, LLC
AstraZeneca
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
AbbVie
AbbVie
Incyte Corporation
Spectrum Pharmaceuticals, Inc
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
Celgene
PharmaMar
Canadian Cancer Trials Group
Takeda
Pfizer
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Santa Maria Biotherapeutics
University of Southern California
ImmunoGen, Inc.
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)